If you have used this antibody, please help fellow researchers by submitting reviews to pAbmAbs and antYbuddY.
Description
Alpha Synuclein is implicated in the regulation of dopamine release and transport. It is a soluble protein, expressed principally in the brain but also expressed in low concentrations in all tissues examined (except liver). In the nervous system, alpha Synuclein is primarily located at presynaptic terminals and is found membrane bound in dopaminergic neurons. It can form filamentous aggregates that are the major non amyloid component of intracellular inclusions in several neurodegenerative diseases (synucleinopathies), including Parkinson's Disease. Alpha Synuclein induces fibrillization of microtubule associated protein tau and reduces neuronal responsiveness to various apoptotic stimuli, leading to a decreased caspase 3 activation. Alpha synuclein is a protein phosphorylated predominantly on serine residues. Additional splicing may be present but the full-length nature of these variants has not been determined. This variant (NACP112) lacks an alternate in-frame segment, compared to variant NACP140, resulting in a shorter protein (isoform NACP112) that has a distinct C-terminus, compared to isoform NACP140. This antibody recognizes both NACP112 and NCAP140. This SNCA antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 75-104 amino acids from the C-terminal region of human SNCA.
Immunogen
Human SNCA.
Other Names
NACP; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; SYN; SYUA; alpha-synuclein; synuclein; alpha; PARK1; SNCA; PD1; PARK4; synuclein, alpha (non A4 component of amyloid precursor); non A-beta component of AD amyloid; synuclein alpha-140; alpha (non A4 component of amyloid precursor); MGC110988; TLR7-like